Disc Medicine shares are trading higher after the company announced data from its ongoing Phase 2 open-label BEACON trial evaluating bitopertin in patients with erythropoietic protoporphyria and X-linked protoporphyria at the EHA 2023 Congress.
Portfolio Pulse from Benzinga Newsdesk
Disc Medicine shares are trading higher following the announcement of positive data from its ongoing Phase 2 BEACON trial evaluating bitopertin in patients with erythropoietic protoporphyria and X-linked protoporphyria at the EHA 2023 Congress.
June 09, 2023 | 2:11 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Disc Medicine shares are trading higher after positive data from its ongoing Phase 2 BEACON trial evaluating bitopertin in patients with erythropoietic protoporphyria and X-linked protoporphyria.
The positive data from the ongoing Phase 2 BEACON trial indicates that the company's bitopertin treatment is showing promising results in patients with erythropoietic protoporphyria and X-linked protoporphyria. This news is likely to boost investor confidence in Disc Medicine and lead to a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100